Cell-based protein vaccines for influenza.
An overview of influenza vaccines in development is provided, with an emphasis on new cell-based protein vaccine candidates. The current licensed vaccine is a cost-effective means to reduce the impact of influenza with a known mechanism of action. Most vaccine companies are focusing on the production of whole influenza viruses in various cell lines to replace egg-based manufacturing technology. Only a limited number of targets have been identified for the development of cell-based protein influenza vaccines. They include hemagglutinin, neuraminidase, M2 and nucleocapsid protein. These protein-based vaccine candidates are discussed, along with their progress in clinical development and the advantages and disadvantages of each vaccine approach.
Cox
Manon M J
MM
Protein Sciences Corporation, Meriden, CT 06450, USA. manon.cox@proteinsciences.com
D000818:Animals; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control*; D009439:Neuraminidase / Q000276:immunology; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology; D014758:Viral Core Proteins / Q000276:immunology; D014763:Viral Matrix Proteins / Q000276:immunology; D014764:Viral Proteins / Q000276:immunology; D000086082:Viroporin Proteins
D007252:Influenza Vaccines; D009439:Neuraminidase; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins; D011994:Recombinant Proteins; D014758:Viral Core Proteins; D014763:Viral Matrix Proteins; D014764:Viral Proteins; C488937:M2 protein, Influenza A virus; D000086082:Viroporin Proteins; C487630:NA protein, influenza A virus